Step Pharma Announces First Patient Dosed with STP938, the

PRESS RELEASE

Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas

• Potential first-in-class focused therapy for relapsed/refractory T cell and B cell lymphomas

St. Genis-Pouilly, France, 24 October 2022 – Step Pharma, the world chief in CTPS1 inhibition for the focused therapy of most cancers, publicizes in the present day that the first affected person has been efficiently dosed with STP938, in a Phase 1/2 trial in grownup topics with relapsed/refractory B cell and T cell lymphomas.

The dose-escalation a part of the open label, non-randomised Phase 1/2 trial contains a number of cohorts dosed with STP938, administered as an oral monotherapy, ascending in a stepwise method. The main goal in Phase I is to evaluate the security and tolerability of STP938.

Brian Schwartz, Chief Medical Officer of Step Pharma, commented: “We are developing STP938, a highly selective, first-in-class treatment based on ground-breaking genetics. The dosing of the first patient into our Phase 1/2 trial is an important step to identify an optimal dose to take forward into further clinical development for relapsed/ refractory T cell and B cell lymphomas.”

STP938 is a first-in-class oral most cancers therapeutic that particularly inhibits nucleotide synthesis and the enzyme cytidine triphosphate synthase 1 (CTPS1) specifically, initially recognized as an important gene for lymphocyte proliferation. By focusing on CTPS1, Step Pharma has unlocked the capacity to selectively goal the de novo pyrimidine synthesis pathway in most cancers cells. This ground-breaking strategy ought to allow the extremely selective therapy of each blood cancers and stable tumours.

Further particulars of the examine could be discovered on clinicaltrials.gov underneath the identifier NCT05463263.

-Ends-

About Step Pharma
Step Pharma’s aim is to convey a few step change in how most cancers is handled with focused therapies that kill most cancers cells and go away wholesome cells unhurt. The Company is the world chief in CTPS1 inhibition, a brand new strategy with the potential to yield extremely selective, secure and efficient most cancers therapies for each blood cancers and stable tumours.

The Company’s lead product STP938 has acquired each IND and CTA clearance to proceed into first in human trials in the US and UK for the therapy of T cell and B cell lymphomas. Clinical trials in lymphoma commenced in September 2022. STP938 has the potential to be the spine of a mess of most cancers therapies in addition to a potent monotherapy for hard-to-treat blood cancers.

Step Pharma was based in 2014 by Kurma Partners, the Imagine Institute and Sygnature Discovery, based mostly on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour. Step Pharma relies in Saint-Genis-Pouilly, France, and is supported by a robust syndicate of traders led by Kurma Partners and together with Bpifrance (Fonds Biothérapies Innovantes et Maladies Rares and InnoBio2 Fund), Pontifax, Hadean Ventures, Sunstone Life Science Ventures, Inserm Transfert Initiative, Idinvest, Sygnature Discovery and the Imagine Institute. More data on the firm could be discovered at www.step-ph.com.

For extra data please contact:

Step Pharma
Andrew Parker, Chief Executive Officer
[email protected]

Consilium Strategic Communications
Amber Fennell, Namrata Taak, Stella Lempidaki
Tel: +44 (0) 20 3709 5700
[email protected]